Client News
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
27th October 2021
Adocia announces 2021 third quarter financial results and a financing of €7 million through the issuance of convertible bonds subscribed by European investors and ordinary shares subscribed by Gérard Soula, Adocia co-founder
27th October 2021
Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France
27th October 2021
Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases
26th October 2021
Andera Partners supports Exciva in a Series A to fight Alzheimer’s disease
26th October 2021
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
26th October 2021
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy
20th October 2021
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
19th October 2021
MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
13th October 2021
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
12th October 2021
There is no more content to load